StockMacro
Menu

Indaptus Therapeutics

$2.82 +154% in 6 monthsMarket cap $433.2M

INDP on XNAS, Health Care, Indaptus Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 131% in six months but the company lost $13.5M over the last year.

  • WatchCash on the balance sheet stands at $30.6M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Industry
Pharmaceutical preparations (Health Care)
Employees
5
Website
indaptusrx.com
Listed
Nasdaq, US
Last results
13 Nov 2026
Next results
expected around 14 May 2027 (an estimate: a year ago it reported on 15 May 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $1.0M.
Quarter to 31 Dec 2021: revenue –, net income -$3.2MQuarter to 31 Mar 2022: revenue –, net income -$3.4MQuarter to 30 Jun 2022: revenue –, net income -$3.8MQuarter to 30 Sep 2022: revenue –, net income -$3.5MQuarter to 31 Dec 2022: revenue –, net income -$3.7MQuarter to 31 Mar 2023: revenue –, net income -$4.3MQuarter to 30 Jun 2023: revenue –, net income -$3.2MQuarter to 30 Sep 2023: revenue –, net income -$3.9MQuarter to 31 Dec 2023: revenue –, net income -$4.0MQuarter to 31 Mar 2024: revenue –, net income -$3.8MQuarter to 30 Jun 2024: revenue –, net income -$4.0MQuarter to 30 Sep 2024: revenue –, net income -$3.1MQuarter to 31 Dec 2024: revenue –, net income -$4.1MQuarter to 31 Mar 2025: revenue –, net income -$4.5MQuarter to 30 Jun 2025: revenue –, net income -$5.2MQuarter to 30 Sep 2025: revenue –, net income -$3.0MQuarter to 31 Dec 2025: revenue –, net income -$8.1MQuarter to 31 Mar 2026: revenue –, net income -$2.5MQuarter to 30 Jun 2026: revenue –, net income -$1.8MQuarter to 30 Sep 2026: revenue –, net income -$1.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $8.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$1.0M
30 Jun 2026–-$1.8M
31 Mar 2026–-$2.5M
31 Dec 2025–-$8.1M
30 Sep 2025–-$3.0M
30 Jun 2025–-$5.2M
31 Mar 2025–-$4.5M
31 Dec 2024–-$4.1M
30 Sep 2024–-$3.1M
30 Jun 2024–-$4.0M
31 Mar 2024–-$3.8M
31 Dec 2023–-$4.0M
30 Sep 2023–-$3.9M
30 Jun 2023–-$3.2M
31 Mar 2023–-$4.3M
31 Dec 2022–-$3.7M
30 Sep 2022–-$3.5M
30 Jun 2022–-$3.8M
31 Mar 2022–-$3.4M
31 Dec 2021–-$3.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$13.5M -$16.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -181% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $30.6M $5.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.07
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 41.9 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Indaptus TherapeuticsINDP (this company) $433.2Mloss–––
EvolusEOLS $431.5Mloss1.3+14%-9.6%
Aquestive TherapeuticsAQST $434.9Mloss8.9+13%-162%
Capricor TherapeuticsCAPR $441.3Mloss–––
Lyell ImmunopharmaLYEL $441.8Mlossover 999-63%–
CytomX TherapeuticsCTMX $442.5Mloss31.5-88%-609%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

0.6%

912K shares held by 13F filers (30 Sep 2026) of 153.6M outstanding (13 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.7%

1.1M shares sold short (30 Oct 2026) of 153.6M outstanding (13 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.0

1.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+33%

857K shares sold short in the report before, 1.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

59%

59% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 44%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

6

6 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.0×

6 articles in the last 7 days; its usual week has 1.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 1.1M, 98× a year earlier

Price $2.82 on 20 Nov 2026, +61% over 12 months (12-month range $0.94 to $4.75)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 20 13F filers reported holding it in the latest 13F quarter, +300% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeShort interest spike: short interest spike, 1.1M vs usual 64K (2026-10-30); 98.0x the same period a year earlier
27 Oct 2026Sharp changeShort interest spike: short interest spike, 857K vs usual 56K (2026-10-15); 47.9x the same period a year earlier
13 Oct 2026Sharp changeShort interest spike: short interest spike, 822K vs usual 56K (2026-09-30); 4.0x the same period a year earlier
29 Sep 2026Sharp changeShort interest spike: short interest spike, 916K vs usual 56K (2026-09-15); 1.7x the same period a year earlier
4 Sep 20268-K and other filingsDirector or officer change
4 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Jun 20268-K and other filingsDirector or officer change
23 Apr 20268-K and other filingsDirector or officer change
3 Apr 20268-K and other filingsDirector or officer change
24 Mar 20268-K and other filingsDirector or officer change
20 Jan 20268-K and other filingsDirector or officer change
8 Jan 20268-K and other filingsDirector or officer change
2 Jan 20268-K and other filingsDirector or officer change
23 Dec 20258-K and other filingsDirector or officer change
23 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Sep 2025Sharp changeShort interest spike: short interest spike, 547K vs usual 71K (2025-09-15); 61.5x the same period a year earlier
3 Sep 20258-K and other filingsRegistered new securities for sale (S-1)
2 Sep 20258-K and other filingsRegistered new securities for sale (S-1)
1 Jul 2025Sharp changeShort interest spike: short interest spike, 748K vs usual 62K (2025-06-13); 143.5x the same period a year earlier
20 Jun 20258-K and other filingsPrivate placement of securities (Form D)
17 Jun 2025Sharp changeShort interest spike: short interest spike, 1.0M vs usual 55K (2025-05-30); 65.8x the same period a year earlier
12 Feb 20258-K and other filingsRegistered new securities for sale (S-1)
31 Jan 20258-K and other filingsDelisting notice or listing transfer
22 Jan 20258-K and other filingsPrivate placement of securities (Form D)
23 Dec 20248-K and other filingsRegistered new securities for sale (S-1)
6 Dec 20248-K and other filingsPrivate placement of securities (Form D)
12 Sep 20248-K and other filingsRegistered new securities for sale (S-1)
22 Aug 20248-K and other filingsPrivate placement of securities (Form D)
7 Jun 20248-K and other filingsDirector or officer change
7 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Mar 20238-K and other filingsDirector or officer change
14 Feb 20238-K and other filingsDirector or officer change
14 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Dec 20228-K and other filingsRegistered new securities for sale (S-1)
1 Feb 20228-K and other filingsDirector or officer change
3 Jan 20228-K and other filingsDirector or officer change
2 Dec 20218-K and other filingsDirector or officer change
2 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Feb 2022: -$100K published
Month from 1 Jun 2022: $52K published
Month from 1 Sep 2022: $54K published
Month from 1 Nov 2022: $19K published
Month from 1 Dec 2022: $3K published
Month from 1 Aug 2023: $216K published
Capital spending per quarter
Quarter ended 31 Dec 2021: $0; public on 22 Mar 2022
Institutional holders (13F filers)
31 Dec 2021 report: 15; public on 14 Feb 2022
31 Mar 2022 report: 17; public on 16 May 2022
30 Jun 2022 report: 16; public on 15 Aug 2022
30 Sep 2022 report: 17; public on 14 Nov 2022
31 Dec 2022 report: 18; public on 14 Feb 2023
31 Mar 2023 report: 15; public on 15 May 2023
30 Jun 2023 report: 13; public on 14 Aug 2023
30 Sep 2023 report: 15; public on 14 Nov 2023
31 Dec 2023 report: 19; public on 14 Feb 2024
31 Mar 2024 report: 16; public on 15 May 2024
30 Jun 2024 report: 20; public on 14 Aug 2024
30 Sep 2024 report: 16; public on 14 Nov 2024
31 Dec 2024 report: 19; public on 14 Feb 2025
31 Mar 2025 report: 17; public on 15 May 2025
30 Jun 2025 report: 4; public on 14 Aug 2025
30 Sep 2025 report: 5; public on 14 Nov 2025
31 Dec 2025 report: 4; public on 17 Feb 2026
31 Mar 2026 report: 6; public on 15 May 2026
30 Jun 2026 report: 9; public on 14 Aug 2026
30 Sep 2026 report: 20; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it had 1.1M shares sold short in the 30 Oct 2026 report, 98× the same report last year; it also had 857K shares sold short in the 15 Oct 2026 report, 48× the same report last year. 4 sharp changes in all.
  • Short interest spike: had 1.1M shares sold short in the 30 Oct 2026 report, 98× the same report last year Public on 11 Nov 2026.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
  • Capital spending per quarter: Capital spending $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 10 insider trades

No trades in the last 90 days; the latest was filed 16 Aug 2023. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
16 Aug 2023Glen R. Anderson10% ownerBuy103,352$2.09$216KForm 4
19 Dec 2022Boyan Vesselinov LitchevChief Medical OfficerBuy1,150$2.19$3KForm 4
22 Nov 2022Jeffrey A MecklerCEO and DirectorBuy10,000$1.89$19KForm 4
12 Sep 2022Jeffrey A MecklerCEO and DirectorBuy10,308$2.80$29KForm 4
9 Sep 2022Walt Addison LinscottChief Business OfficerBuy150$2.62$393Form 4
8 Sep 2022Jeffrey A MecklerCEO and DirectorBuy9,692$2.56$25KForm 4
7 Jun 2022Jeffrey A MecklerCEO and DirectorBuy19,727$2.63$52KForm 4
2 Feb 2022Michael James NewmanCSO and DirectorSell20,000$5.00$100KForm 4

20 institutions reported shares at the end of Q3 2026, 1% of the shares outstanding; 12 opened a position, 1 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Geode Capital Management, LLC196K0.13%$450K+139K+246%
Vanguard Capital Management LLC136K0.09%$313K+102K+304%
Jane Street Group, LLC86K0.06%$199K+33K+61%
UBS Group AG83K0.05%$192K+83K174 times as many
Marshall Wace, LLP78K0.05%$179KNew+78K
Millennium Management LLC72K0.05%$166K+60K+522%
Vanguard Fiduciary Trust Co65K0.04%$150K+51K+368%
State Street Corp64K0.04%$147KNew+64K
Virtu Financial LLC35K0.02%New+35K
Jump Financial, LLC28K0.02%$64KNew+28K

Company events

All 53 company events

In 12 months: 9 director or officer changes, 6 major agreements. Results releases and routine reports are left out.

FiledWhat happenedSource
30 Sep 2026Signed a major agreement8-K
9 Sep 2026Signed a major agreementSame filing: sold shares privately8-K
4 Sep 2026Director or officer change8-K
1 Sep 2026Signed a major agreement8-K
24 Jun 2026Signed a major agreementSame filing: sold shares privately8-K
5 Jun 2026Director or officer change8-K
22 Apr 2026Director or officer change8-K
3 Apr 2026Director or officer change8-K

The 5 newest of 59 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 11 Nov 2026Short interest and volume change

    had 1.1M shares sold short in the 30 Oct 2026 report, 98× the same report last year.

    Same report last year: 12K; its normal report is 64K.

    See the evidence
    This period
    1.1M (the 30 Oct 2026 report)
    Normal report (median of 24 earlier)
    64K
    Typical spread (median absolute deviation)
    52K
    How far from its usual level
    +14.1
    Same report last year
    12K
    History used
    1,904 days
    2025-10-31: 12K2025-11-14: 11K2025-11-28: 14K2025-12-15: 18K2025-12-31: 260K2026-01-15: 68K2026-01-30: 19K2026-02-13: 18K2026-02-27: 19K2026-03-13: 8,6422026-03-31: 13K2026-04-15: 53K2026-04-30: 70K2026-05-15: 60K2026-05-29: 17K2026-06-15: 493K2026-06-30: 138K2026-07-15: 260K2026-07-31: 93K2026-08-14: 124K2026-08-31: 212K2026-09-15: 916K2026-09-30: 822K2026-10-15: 857K2026-10-30: 1.1M
    the 30 Oct 2026 report24 earlier reportsnormal: 64K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 27 Oct 2026Short interest and volume change

    had 857K shares sold short in the 15 Oct 2026 report, 48× the same report last year.

    Same report last year: 18K; its normal report is 56K.

    See the evidence
    This period
    857K (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    56K
    Typical spread (median absolute deviation)
    43K
    How far from its usual level
    +12.7
    Same report last year
    18K
    History used
    1,889 days
    2025-10-15: 18K2025-10-31: 12K2025-11-14: 11K2025-11-28: 14K2025-12-15: 18K2025-12-31: 260K2026-01-15: 68K2026-01-30: 19K2026-02-13: 18K2026-02-27: 19K2026-03-13: 8,6422026-03-31: 13K2026-04-15: 53K2026-04-30: 70K2026-05-15: 60K2026-05-29: 17K2026-06-15: 493K2026-06-30: 138K2026-07-15: 260K2026-07-31: 93K2026-08-14: 124K2026-08-31: 212K2026-09-15: 916K2026-09-30: 822K2026-10-15: 857K
    the 15 Oct 2026 report24 earlier reportsnormal: 56K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 10 Oct 2026Short interest and volume change

    had 822K shares sold short in the 30 Sep 2026 report, 4.0× the same report last year.

    Same report last year: 203K; its normal report is 56K.

    See the evidence
    This period
    822K (the 30 Sep 2026 report)
    Normal report (median of 24 earlier)
    56K
    Typical spread (median absolute deviation)
    43K
    How far from its usual level
    +12.1
    Same report last year
    203K
    History used
    1,874 days
    2025-09-30: 203K2025-10-15: 18K2025-10-31: 12K2025-11-14: 11K2025-11-28: 14K2025-12-15: 18K2025-12-31: 260K2026-01-15: 68K2026-01-30: 19K2026-02-13: 18K2026-02-27: 19K2026-03-13: 8,6422026-03-31: 13K2026-04-15: 53K2026-04-30: 70K2026-05-15: 60K2026-05-29: 17K2026-06-15: 493K2026-06-30: 138K2026-07-15: 260K2026-07-31: 93K2026-08-14: 124K2026-08-31: 212K2026-09-15: 916K2026-09-30: 822K
    the 30 Sep 2026 report24 earlier reportsnormal: 56K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 25 Sep 2026Short interest and volume change

    had 916K shares sold short in the 15 Sep 2026 report, 1.7× the same report last year.

    Same report last year: 547K; its normal report is 56K.

    See the evidence
    This period
    916K (the 15 Sep 2026 report)
    Normal report (median of 24 earlier)
    56K
    Typical spread (median absolute deviation)
    43K
    How far from its usual level
    +13.6
    Same report last year
    547K
    History used
    1,859 days
    2025-09-15: 547K2025-09-30: 203K2025-10-15: 18K2025-10-31: 12K2025-11-14: 11K2025-11-28: 14K2025-12-15: 18K2025-12-31: 260K2026-01-15: 68K2026-01-30: 19K2026-02-13: 18K2026-02-27: 19K2026-03-13: 8,6422026-03-31: 13K2026-04-15: 53K2026-04-30: 70K2026-05-15: 60K2026-05-29: 17K2026-06-15: 493K2026-06-30: 138K2026-07-15: 260K2026-07-31: 93K2026-08-14: 124K2026-08-31: 212K2026-09-15: 916K
    the 15 Sep 2026 report24 earlier reportsnormal: 56K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 4 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 4 Sep 2026Filings record

    Director or officer change

  7. 5 Jun 2026Filings record

    Director or officer change

  8. 23 Apr 2026Filings record

    Director or officer change (dated 22 Apr 2026)

  9. 3 Apr 2026Filings record

    Director or officer change

  10. 24 Mar 2026Filings record

    Director or officer change

  11. 20 Jan 2026Filings record

    Director or officer change

  12. 8 Jan 2026Filings record

    Director or officer change

  13. 2 Jan 2026Filings record

    Director or officer change

  14. 23 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 23 Dec 2025Filings record

    Director or officer change

  16. 25 Sep 2025Short interest and volume change

    had 547K shares sold short in the 15 Sep 2025 report, 62× the same report last year.

    Same report last year: 8,899; its normal report is 71K.

    See the evidence
    This period
    547K (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    71K
    Typical spread (median absolute deviation)
    40K
    How far from its usual level
    +8.0
    Same report last year
    8,899
    History used
    1,494 days
    2024-09-13: 8,8992024-09-30: 34K2024-10-15: 31K2024-10-31: 139K2024-11-15: 85K2024-11-29: 92K2024-12-13: 93K2024-12-31: 75K2025-01-15: 66K2025-01-31: 39K2025-02-14: 78K2025-02-28: 58K2025-03-14: 52K2025-03-31: 221K2025-04-15: 131K2025-04-30: 120K2025-05-15: 81K2025-05-30: 1.0M2025-06-13: 748K2025-06-30: 30K2025-07-15: 15K2025-07-31: 11K2025-08-15: 19K2025-08-29: 15K2025-09-15: 547K
    the 15 Sep 2025 report24 earlier reportsnormal: 71K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 3 Sep 2025Filings record

    Registered new securities for sale (S-1)

  18. 2 Sep 2025Filings record

    Registered new securities for sale (S-1)

  19. 26 Jun 2025Short interest and volume change

    had 748K shares sold short in the 13 Jun 2025 report, 144× the same report last year.

    Same report last year: 5,212; its normal report is 62K.

    See the evidence
    This period
    748K (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    62K
    Typical spread (median absolute deviation)
    40K
    How far from its usual level
    +11.6
    Same report last year
    5,212
    History used
    1,400 days
    2024-06-14: 5,2122024-06-28: 5,6952024-07-15: 14K2024-07-31: 8,0812024-08-15: 7,1342024-08-30: 3,6632024-09-13: 8,8992024-09-30: 34K2024-10-15: 31K2024-10-31: 139K2024-11-15: 85K2024-11-29: 92K2024-12-13: 93K2024-12-31: 75K2025-01-15: 66K2025-01-31: 39K2025-02-14: 78K2025-02-28: 58K2025-03-14: 52K2025-03-31: 221K2025-04-15: 131K2025-04-30: 120K2025-05-15: 81K2025-05-30: 1.0M2025-06-13: 748K
    the 13 Jun 2025 report24 earlier reportsnormal: 62K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 20 Jun 2025Filings record

    Private placement of securities (Form D)

  21. 11 Jun 2025Short interest and volume change

    had 1.0M shares sold short in the 30 May 2025 report, 66× the same report last year.

    Same report last year: 16K; its normal report is 55K.

    See the evidence
    This period
    1.0M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    55K
    Typical spread (median absolute deviation)
    38K
    How far from its usual level
    +17.0
    Same report last year
    16K
    History used
    1,386 days
    2024-05-31: 16K2024-06-14: 5,2122024-06-28: 5,6952024-07-15: 14K2024-07-31: 8,0812024-08-15: 7,1342024-08-30: 3,6632024-09-13: 8,8992024-09-30: 34K2024-10-15: 31K2024-10-31: 139K2024-11-15: 85K2024-11-29: 92K2024-12-13: 93K2024-12-31: 75K2025-01-15: 66K2025-01-31: 39K2025-02-14: 78K2025-02-28: 58K2025-03-14: 52K2025-03-31: 221K2025-04-15: 131K2025-04-30: 120K2025-05-15: 81K2025-05-30: 1.0M
    the 30 May 2025 report24 earlier reportsnormal: 55K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 12 Feb 2025Filings record

    Registered new securities for sale (S-1)

  23. 31 Jan 2025Filings record

    Delisting notice or listing transfer

  24. 22 Jan 2025Filings record

    Private placement of securities (Form D)

  25. 23 Dec 2024Filings record

    Registered new securities for sale (S-1)

  26. 6 Dec 2024Filings record

    Private placement of securities (Form D)

  27. 12 Sep 2024Filings record

    Registered new securities for sale (S-1)

  28. 22 Aug 2024Filings record

    Private placement of securities (Form D)

  29. 7 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 7 Jun 2024Filings record

    Director or officer change

  31. 17 Aug 2023Insiders record

    Anderson Glen R. (ten percent owner) bought 103,352 shares of INDP ($216,388) (dated 16 Aug 2023)

  32. 23 Mar 2023Filings record

    Director or officer change

  33. 14 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 14 Feb 2023Filings record

    Director or officer change

  35. 23 Dec 2022Filings record

    Registered new securities for sale (S-1)

  36. 20 Dec 2022Insiders record

    Litchev Boyan Vesselinov (Chief Medical Officer) bought 1,150 shares of INDP ($2,520) (dated 19 Dec 2022)

  37. 23 Nov 2022Insiders record

    Meckler Jeffrey A (CEO and Director) bought 10,000 shares of INDP ($18,944) (dated 22 Nov 2022)

  38. 13 Sep 2022Insiders record

    Meckler Jeffrey A (CEO and Director) bought 10,308 shares of INDP ($28,862) (dated 12 Sep 2022)

  39. 10 Sep 2022Insiders record

    Linscott Walt Addison (Chief Business Officer) bought 150 shares of INDP ($393) (dated 9 Sep 2022)

  40. 9 Sep 2022Insiders record

    Meckler Jeffrey A (CEO and Director) bought 9,692 shares of INDP ($24,771) (dated 8 Sep 2022)

Showing the newest 40 of 60 entries; narrow the window or the kind of data to see older ones.

Not listed: 80 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001857044
Ticker
INDP
Domain
indaptusrx.com
Hq location
NY|NEW YORK|10019 (1 unverified)
Name
Indaptus Therapeutics, Inc., Intec Parent Inc.
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)117 records22 Jun 2021 to 13 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)300 data points31 Dec 2019 to 13 Nov 2026
  • SEC Form 4 insider transactions10 records, 40 data points16 Sep 2021 to 16 Aug 2023
  • FINRA short interest (twice monthly)374 data points13 Aug 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2664 data points4 Aug 2021 to 20 Nov 2026